Dr. Thomas Herzog on the Cautions of Interval Debulking Surgery in Ovarian Cancer
November 25th 2015Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.
Watch
Dr. Rimas Lukas on the Future of Checkpoint Inhibitors in Recurrent Glioblastoma
November 20th 2015Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, on PD-L1 blockade treatment and its potential in patients with recurrent glioblastoma (GBM).
Watch
Dr. Suresh Ramalingam on Immune Checkpoint Inhibitors in NSCLC Treatment
November 20th 2015Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Watch
Dr. Howard A. Burris, III, on Modern Chemotherapy for Patients with HER2-Positive Breast Cancer
November 20th 2015Howard A. "Skip" Burris, III, MD, president, Clinical Operations, chief medical officer and executive director of Drug Development, Sarah Cannon, talks about chemotherapy in the era of personalized medicine.
Watch
Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast Cancer
November 19th 2015Mohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab.
Watch
Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer
November 18th 2015Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Watch
Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung Cancer
November 14th 2015Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.
Watch
Dr. Aaron Spitz on the Role of Telemedicine in Urology
November 12th 2015Aaron Spitz, MD, talks about the emerging uses of telemedicine in urology. Telemedicine allows medical professionals to remotely diagnose and sometimes even treat patients through a variety of technology, including smartphones and tablet devices.
Watch
Dr. Sylvia Adams on Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer
November 12th 2015Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium.
Watch
Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients
November 11th 2015John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Watch
Dr. Ghassan Abou-Alfa on Possible Second-Line Treatments for HCC Patients
November 11th 2015Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.
Watch
Dr. Jeffrey Infante on the Positive Results of Using Avelumab in Patients With Ovarian Cancer
November 10th 2015Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.
Watch